Towa closes acquisition of Esteve's generics division

Towa Pharmaceutical has completed its acquisition of Esteve's generics division, including Breckenridge.

Towa, based in Osaka, Japan, has been dedicated to the research and development, production, and marketing of generic drugs since 1951. With a team of more than 3,100 employees, its annual sales were 105,104 million yen for the year ended March 31, 2019. Towa's shares are listed on the Tokyo Stock Exchange.

Breckenridge markets a broad range of generic prescription products in several therapeutic categories and dosage forms.